Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 04 Jan 2022
Daratumumab in multiple myeloma: reassessment results in hint of considerable added benefit
3 January 2022 - Janssen applied for a new early benefit assessment due to new scientific findings. ...
Posted by Michael Wonder on 04 Jan 2022
Genprex receives U.S. FDA fast track designation for Reqorsa immunogene therapy in combination with Keytruda for the treatment of non-small-cell lung cancer
3 January 2022 - Second FDA fast track designation further validates the potential of Reqorsa. ...
Posted by Michael Wonder on 04 Jan 2022
Novavax submits final data packages to U.S. FDA as prerequisite to Emergency Use Authorisation application request for COVID-19 Vaccine
30 December 2021 - EUA application request to be submitted following one month required by FDA EUA guidance. ...
Posted by Michael Wonder on 03 Jan 2022
FDA grants ILiAD Biotechnologies fast track designation for next generation pertussis vaccine BPZE1
3 January 2021 - ILiAD Biotechnologies, today announced that the U.S. FDA has granted fast track designation to BPZE1, a next ...
Posted by Michael Wonder on 03 Jan 2022
FDA takes multiple actions to expand use of Pfizer-BioNTech COVID-19 Vaccine
3 January 2021 - Today, the U.S. FDA amended the emergency use authorisation for the Pfizer-BioNTech COVID-19 Vaccine to: ...
Posted by Michael Wonder on 01 Jan 2022
Paion submits extension application of marketing authorisation for remimazolam in the indication general anaesthesia to the European Medicines Agency
31 December 2021 - Paion today announces that it has submitted an extension application to the marketing authorisation for remimazolam ...
Posted by Michael Wonder on 01 Jan 2022
Xeris Biopharma announces U.S. FDA approval of Recorlev (levoketoconazole) for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome
30 December 2021 - FDA approval supported by positive results from the pivotal Phase 3 SONICS and LOGICS studies demonstrating Recorlev ...
Posted by Michael Wonder on 31 Dec 2021
Schedule of Pharmaceutical Benefits - 1 January 2022 update
1 January 2022 - The January 2022 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 31 Dec 2021
New Zealand Pharmaceutical Schedule - 1 January 2022
1 January 2022 - The January 2022 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 31 Dec 2021
Celltrion acquires approval for its new Humira 'Yuflyma' in Canada
30 December 2021 - Celltrion announced on December 30 that it won marketing approval from Health Canada for "Yuflyma", a ...
Posted by Michael Wonder on 31 Dec 2021
FDA accepts Arcutis Biotherapeutics’ new drug application for roflumilast cream for adults and adolescents with plaque psoriasis
22 December 2021 - FDA has set a target action date of 29 July 2022. ...
Posted by Michael Wonder on 31 Dec 2021
Lexicon submits new drug application for sotagliflozin for the treatment of heart failure in adults with type 2 diabetes
30 December 2021 - ) -- Lexicon Pharmaceuticals today announced that it has submitted a new drug application to the U.S. ...
Posted by Michael Wonder on 31 Dec 2021
Amylyx Pharmaceuticals announces FDA acceptance and priority review of new drug application for AMX0035 for the treatment of ALS
29 December 2021 - Amylyx Pharmaceuticals today announced that the U.S. FDA has accepted for review its new drug application for ...
Posted by Michael Wonder on 30 Dec 2021
Janssen submits biologics license application to U.S. FDA seeking approval of teclistamab for the treatment of patients with relapsed or refractory multiple myeloma
29 December 2021 - Janssen announced today the submission of a biologics license application to the U.S. FDA seeking approval ...
Posted by Michael Wonder on 30 Dec 2021
PBS listing for Braftovi and cetuximab for metastatic bowel cancer patients with BRAFV600 mutation
30 December 2021 - Pierre Fabre Australia today announced that Braftovi (encorafenib) in combination with cetuximab will be listed on the ...